Azacitidine Injection

Phase 1/2Withdrawn

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Tuberculosis, Pulmonary

Conditions

Tuberculosis, Pulmonary

Trial Timeline

Oct 1, 2022 → May 1, 2023

NCT ID

NCT03941496

About Azacitidine Injection

Azacitidine Injection is a phase 1/2 stage product being developed by Bristol Myers Squibb for Tuberculosis, Pulmonary. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03941496. Target conditions include Tuberculosis, Pulmonary.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03941496	Phase 1/2	Withdrawn	Oct 1, 2022	May 1, 2023	Tuberculosis, Pulmonary

Competing Products

20 competing products in Tuberculosis, Pulmonary

See all competitors

Product	Company	Stage	Hype Score
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusion	Shionogi	Phase 1	33
BCG Vaccine USP + Isoniazid + Rifampin	Merck	Phase 1	33
MK-7762 (TBD09)	Merck	Phase 1	33
Doravirine (DOR) + Rifapentine (RPT) + Isoniazid (INH)	Merck	Phase 1	33
Indacaterol + Control	Novartis	Phase 3	77
Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1	Novartis	Phase 1	33
Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid	Novartis	Phase 2	52
Rifampicin + Isoniazid + Pyrazinamide + Kanamycin + Moxifloxacin	Novartis	Phase 1	33
Rifapentine daily + Rifapentine weekly	Gilead Sciences	Approved	84
rifabutin	Pfizer	Pre-clinical	22
Linezolid + Ethambutol	Pfizer	Phase 2	51
Myrin© 2 (Rifampicin + Isoniazid) + Rimactane® (Rifampicin)	Pfizer	Phase 1	32
Rifapentine + Isoniazid	Sanofi	Phase 1/2	40
AERAS-404 + Placebo + Bacillus Calmette-Guérin (BCG)	Sanofi	Phase 2	51
rifampin + rifapentine + rifapentine + rifapentine	Sanofi	Phase 2	51
rifapentine (M000473) + EFZ EMT TDF	Sanofi	Phase 1	32
Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin	Sanofi	Phase 3	76
Rifampicin in higher doses	Sanofi	Phase 2	51
Higher-Dose Rifampin	Sanofi	Phase 2	51
Rifampin & midazolam + rifapentine & midazolam + rifapentine & midazolam + rifapentine & midazolam + rifapentine and midazolam + rifapentine and midazolam	Sanofi	Phase 1	32

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved